Innoviva, Inc. (HVE.F)
| Previous Close | 14.00 |
| Open | 14.20 |
| Bid | 14.40 x 33200 |
| Ask | 14.50 x 32300 |
| Day's Range | 14.20 - 14.20 |
| 52 Week Range | 10.50 - 15.40 |
| Volume | |
| Avg. Volume | 1 |
| Market Cap | 910.718M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 6.93 |
| EPS (TTM) | 2.05 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Sept 08, 2015 |
| 1y Target Est | N/A |
Business WireInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
WALTHAM, Mass., April 24, 2024--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain. Zoliflodacin is a first
Simply Wall St.Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Innoviva's (NASDAQ:INVA) recent performance, when its stock has declined 10...
PR NewswireArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
